Secnidazole for use in the treatment of bacterial vaginosis

A method of treating bacterial vaginosis in a subject in need thereof comprising:

• administering to the subject a therapeutically effective amount of secnidazole in a microgranule formulation, wherein the microgranule formulation comprises a plurality of microgranules having a volume-weighted particle size distribution within a microgranule population, wherein the volume-weighted particle size distribution as measured from a representative sample of the microgranule population comprises:
• (a) 10% of the microgranule population having a volume-weighted particle size about no less than 470 micrometers;
• (b) 50% of the microgranule population having a volume-weighted particle size between about no less than 640 micrometers and about no more than 810 micrometers;
• (c) 90% of the microgranule population having a volume-weighted particle size about no more than 1170 micrometers;
• or
• (d) a combination thereof, which can include some or all of (a) through (c) above;
• wherein the therapeutically effective amount of secnidazole is an amount of secnidazole that exhibits a maximum plasma concentration (Cmax) of secnidazole in the subject of about 8 ng/ml to about 11 ng/ml, about 34.5 μg/ml to about 58.3 μg/ml, or about 17.4 μg/ml to about 26.5 μg/ml;
• and
• wherein secnidazole is the sole drug in the microgranule formulation.